GitLife 2.0: Utilising next generation digital technologies to deliver twenty-fold improvement to a unique version control system, enabling SynBio innovations in net zero and healthcare.

GitLife 2.0：利用下一代数字技术为独特的版本控制系统提供二十倍的改进，从而实现 SynBio 在净零排放和医疗保健领域的创新。

• 批准号: 10077100
• 金额: $ 31.77万
• 依托单位: GITLIFE BIOTECH LTD
• 依托单位国家: 英国
• 项目类别: Investment Accelerator
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10077100
• 关键词: GitLife; 2.0; Utilising; next; generation

Synthetic Biology (SynBio) is the application of engineering principles to biology. Synthetic Biologists think of proteins as machines, composed of multiple different components, each encoded by genes or parts of genes. By rearranging genes, they can make proteins with new functions. SynBio also uses computer modelling heavily, mapping what genes should go where in designs for new biological machine. SynBio aims to solve problems in energy, food production and human health by optimising biological machines. Lots of grant funding and private investment has poured into SynBio research. However, there are no reliable systems to match engineered organisms with records of how they were constructed. Because commercial competitors can copy engineered organisms relatively easily, many new ideas fail to be commercialised. It is also critical that companies using SynBio can provide government agencies who regulate SynBio with absolute proof that they are using the strain they say they are.GitLife Biotech (GLB) has developed a system that can insert 'barcode' sequences of DNA into an organism's genome. Anyone can find out the sequence of this barcode and use it to see what a particular strain is. In this project, they want to make this system more secure by using a computer coding system called Elliptical Curve cryptography. They also want to demonstrate that they can insert several barcodes into a strain at different locations. The DNA sequence of these barcodes, combined with their location makes it practically impossible for anyone wanting to copy the strain to remove these identification marks.GLB plans to launch this system onto the market in late 2023\. An investment company called SFC Capital are interested in making an equity investment, provided that GLB can secure a grant to cover some of the costs of making their technology more secure and faster to apply.

合成生物学(SynBio)是工程原理在生物学中的应用。合成生物学家认为蛋白质是由多个不同组件组成的机器，每个组件都由基因或部分基因编码。通过重新排列基因，他们可以制造具有新功能的蛋白质。SynBio还大量使用计算机建模，绘制出在设计新的生物机器时应该去哪里的基因。Synbio的目标是通过优化生物机器来解决能源、食品生产和人类健康方面的问题。大量的赠款资金和私人投资涌入了SynBio的研究。然而，没有可靠的系统来匹配工程生物与它们是如何构建的记录。由于商业竞争对手可以相对容易地复制工程生物，许多新想法未能商业化。同样重要的是，使用SynBio的公司能够向监管SynBio的政府机构提供绝对证据，证明他们使用的是他们所说的菌株。GitLife Biotech(GLB)开发了一种系统，可以将DNA的条形码序列插入生物体的基因组中。任何人都可以找到这种条形码的序列，并使用它来查看特定的菌株是什么。在这个项目中，他们希望通过使用一种名为椭圆曲线密码术的计算机编码系统来使这个系统更加安全。他们还想证明，他们可以在不同位置将几个条形码插入到一个菌株中。这些条形码的DNA序列，再加上它们的位置，使得任何想要复制这种菌株的人几乎不可能移除这些识别标记。GLB计划在2023年底将这一系统投放市场。一家名为SFC Capital的投资公司有兴趣进行股权投资，前提是GLB能够获得拨款，以支付使他们的技术更安全、更快应用的部分成本。